^
    Back
    Association details:
    Biomarker:SOX10 underexpression
    Cancer:Melanoma
    Drug Class:BRAF inhibitor +
    MEK inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    AACR 2021
    Title:

    40 - Targeting SOX10-deficient cells to reduce resistance to targeted therapy in melanoma

    Published date:
    03/10/2021
    Excerpt:
    ...melanoma models...cell lines generated from xenograft tumors that have acquired resistance to either vemurafenib, paradox-breaking BRAFi or the combination of BRAFi + MEKi showed dramatically reduced SOX10 expression compared to their parental counterparts.